Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 14/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6207817 | 0.85 | MMP13 (0.48) | MMP13MMP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6206170 | 0.78 | L3MBTL1 (0.47) | MMP13CYP1A2CYP3A4CYP2D6RARB | |
| SCHEMBL6205985 | 0.77 | CYP2D6 (0.49) | MMP13MMP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6207339 | 0.75 | MMP13 (0.49) | MMP13MMP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8313400 | 0.72 | MMP13 (0.34) | MMP13 | |
| SCHEMBL14569172 | 0.72 | NPC1 (0.50) | MMP13MMP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8312489 | 0.72 | CA2 (0.34) | — | |
| SCHEMBL5908698 | 0.71 | CA12 (0.43) | MMP13MMP1MMP9RARB | |
| SCHEMBL3255184 | 0.71 | NPC1 (0.49) | MMP13MMP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3255085 | 0.70 | MMP13 (0.49) | MMP13MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004048368-A2 | HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |